ALL NEWS TODAY

[ ALL NEWS TODAY ]

Sciele Pharma Announces That Addrenex Has Completed Enrollment Of Pivotal Phase III Trial For Clonicel For ADHD

Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. Addrenex is also continuing to enroll patients in an additional Phase III trial using Clonicel in combination with stimulants such as methylphenidate and dextro-amphetamine/amphetamine to treat ADHD.
Comments: [0] / Post comment:
04 Dec 2008 21:42:26

Around the horn - San Jose Mercury News

Around the horn San Jose Mercury News, USA - Bishop O'Dowd High's Damajeria Dubose had the best finish, placing 14th in the Division III field. The Dragons girls finished 15th as a team. ... Dragons fumble away chance at NCS victory
04 Dec 2008 18:20:38

Mannkind boasts of success in Phase III inhaled-insulin studies - FierceBiotech

Mannkind boasts of success in Phase III inhaled-insulin studies FierceBiotech, DC - "We are very pleased to announce the positive outcome of these, the last of our three pivotal Phase III studies," said Dr. Peter Richardson, ...
04 Dec 2008 17:32:50

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in ... - MarketWatch

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in ... MarketWatch - Nineteen end stage blood cancer patients were treated with no cases of grade III IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, ...
04 Dec 2008 16:49:36

Pozen's pain drug meets endpoint in Phase III studies - Trading Markets (press release)

Pozen's pain drug meets endpoint in Phase III studies Trading Markets (press release), CA - Dec 04, 2008 (Datamonitor via COMTEX) -- POZN Quote Chart News PowerRating -- Pozen, a pharmaceutical company, has announced positive Phase III ... AstraZeneca achieves primary endpoints in two PN 400 late-stage ... Pozen drug clears one hurdle, but another remains Astra trials achieve primary endpoints -
04 Dec 2008 16:19:46

OPKO Health Announces Completion of Enrollment for Its Phase III ... - MarketWatch

OPKO Health Announces Completion of Enrollment for Its Phase III ... MarketWatch - announced today that it has completed enrollment in the Company's Phase III clinical trial of bevasiranib for the treatment of wet age-related macular ...
04 Dec 2008 16:07:00

Osiris Completes Enrollment in First Worldwide Phase III Stem Cell ... - Business Wire (press release)

Osiris Completes Enrollment in First Worldwide Phase III Stem Cell ... Business Wire (press release), CA - The Phase III trial is evaluating the safety and efficacy of Prochymal in conjunction with standard of care for treatment of patients who have failed to ... Osiris Completes Enrollment in First Worldwide Phase III Stem ...
04 Dec 2008 10:07:43

Tuberville Resigns As Auburn Coach - Hartford Courant

The Enterprise Ledger Tuberville Resigns As Auburn Coach Hartford Courant, United States - ... abare on the Football Championship Subdivision (I-AA) team, and Trinity quarterback Eric McGrath and linebacker Tyler Berry on the Division II III team. Wednesday Football Notes, Part III Auburn will use Carr Sports Associates to search for Tubervilles ... Wednesday Auburn Football Notes
04 Dec 2008 10:05:50

Beleaguered LAUSD Superintendent David Brewer III hopes to stay - Contra Costa Times

Beleaguered LAUSD Superintendent David Brewer III hopes to stay Contra Costa Times, CA - By George B. Sánchez, Staff Writer Los Angeles Unified School District superintendent David Brewer III at his downtown Los Angeles office Wednesday, ... Board bungles booting Brewer Pressure Mounts for LAUSDs Brewer to Resign Looking Beyond Funding In Education Reform
04 Dec 2008 10:00:43

Roy Lang III's Week 14 NFL rankings - Shreveport Times

Bleacher Report Roy Lang III's Week 14 NFL rankings Shreveport Times, LA - The top-five teams in this poll won last week. That's probably a first in this wacky season. We are finally beginning to see what group of teams is the best ... NFL Power Rankings: Week 14
04 Dec 2008 08:33:17

Zevalin Data to be Presented at ASH 2008 - MarketWatch

Zevalin Data to be Presented at ASH 2008 MarketWatch - 7, 2008 6:00-8:00 PM 2995 Poster III -77 Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning ... ZEVALIN(R) Data to Be Presented at 2008 Annual Meeting of the ...

Keywords:

ALL NEWS TODAY © PoznaiSebya.Ñom
Designer Dmytriev Dmytriy